4 May 2022

Simmunext: where immunotherapy and chemistry meet

The story behind Oncode’s newest spinoff, Simmunext Biotherapeutics B.V.

Bianca-Olivia Nita

Bianca-Olivia Nita

Simmunext is a company name made of three words - a mix of ‘simulation’ (referring to simulating the immune system), ‘immune’ (referencing the immune system) and ‘next’ (indicating a next-generation approach). This describes the innovative approach Oncode Investigator Carl Figdor has developed to create polymers which can act as artificial antigen-presenting cells to stimulate the immune system to obtain a therapeutic response. With a strong IP position and management team in place, the company is now ready for its journey to leverage this platform technology to bring novel cancer therapies to the clinic.

Decades ago, the scientific community was sceptical. Many thought that cancer was all about genetics and had nothing to do with immunology. But things have changed. Today it is widely known the immune system can contribute to fighting cancer, with successes seen for example in treating lung cancer and melanoma.

There are three types of immunotherapies used nowadays. Antibodies, vaccines and cell therapies, the latter using an effective method of taking cells from the patient, engineering them, then giving them back to the patient so they can fight the cancer they are engineered against.

The lab of Oncode Investigator Carl Figdor has been working with dendritic cells for a long time. These are immune cells that present antigens to T-cells, which then target cancer cells expressing the antigen they are activated against. “I always found that because you are getting these cells from patients, the procedure can be very difficult. Sometimes the patient is not in such a good condition, or they are immunosuppressed. Or we simply don’t get enough cells. The protocol was always variable, because the material we could get from the patients was variable” explains Figdor.

But after connecting with the chemistry department at Radboud University, he got interested in the polymers this department made. “I asked myself - could I try to mimic the immune system? Could I make artificial antigen-presenting cells by using polymers?” Figdor recalls. “Of course, these are not cells, these are polymers. But I could equip them with molecules that can also be found on immune cells”.

Soon enough he received his an ERC advanced grant to develop this idea further and two years ago, received a second one to continue this work, helping him demonstrate what is now clear: that using chemistry to mimic live cells can work. “This also helped me develop the technology – the immunofilaments - that can efficiently make immune cells more fit and more robust for immunotherapy.”

The creation of Simmunext – for which Henri Theunissen will serve as CEO - means bringing a decade of work to the next level and taking steps towards the clinic. “Without Oncode’s support, I wouldn’t so easily have taken this path. As an academic, starting a company never received priority. But the Oncode valorization team – Ian Bell and Shobit Dhawan in particular – stimulated me and convinced me this is the logical next step” explains Figdor.

“We want to develop a therapeutic drug and doing so is extremely expensive, not something an academic hospital can easily afford. We also secured several patents. We are in good shape and now the real work starts” he says with a laugh. “We must make a big step to translate this to the clinic and the next two years are crucial in getting there” he concludes.

Other News

Paper tassos
AlphaFill: filling in the blanks in protein structure prediction
The development of tools like AlphaFold and RoseTTAfold, and more recently of the ESM Metagenomic Atlas and OmegaFold, was a gamechanger in the field of 3D protein structure prediction. However, for many proteins a pivotal piece to the puzzle was still lacking, as most proteins do not function without specific cofactors. New work by the group of Oncode Investigator Anastassis Perrakis at the Netherlands Cancer Institute literally fills this void and brings AlphaFill into the picture. Their work was published today in Nature Methods.
PeterThijssen
Tineke 4
Tineke Lenstra joins the EMBO Young Investigator Programme
EMBO just announced 24 life scientists as the newest members of the EMBO Young Investigator Programme. One of the new members is Oncode Investigator Tineke Lenstra (Netherlands Cancer Institute), with her project on understanding transcriptional bursting in single cells. The Young Investigator Programme supports excellent group leaders who have been in independent positions for less than four years and have an excellent track record of scientific achievements.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Laloes Fotografie 0151 2
Oncode Institute welcomes Marvin Tanenbaum to the Research Management Committee
We are pleased to welcome Oncode Investigator Marvin Tanenbaum (Hubrecht Institute) to Oncode’s Research Management Committee (RMC). Marvin will replace Oncode Investigator Thijn Brummelkamp (NKI), who was part of the RMC for 4 years.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.